Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Scancell Holdings plc (SCLP) Ord GBP0.001

Sell:22.50p Buy:23.00p 0 Change: 1.50p (6.12%)
Market closed |  Prices as at close on 26 February 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:22.50p
Buy:23.00p
Change: 1.50p (6.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 February 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:22.50p
Buy:23.00p
Change: 1.50p (6.12%)
Market closed |  Prices as at close on 26 February 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Contact details

Address:
Department of Clinical Oncology
Hucknall Road
OXFORD
OX4 4GP
United Kingdom
Telephone:
+44 (0115) 8231863
Website:
www.scancell.co.uk/

Important dates

Future events
There are no future events available.
Past events
Interim results 29 January 2021 29/01/21
AGM 17 November 2020 17/11/20
General meeting 05 November 2020 05/11/20
Final results 16 October 2020 16/10/20
General meeting 11 August 2020 11/08/20

General stock information

EPIC:
SCLP
ISIN:
GB00B63D3314
Market cap:
£187.50 million
Shares in issue:
815.22 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Clifford Holloway
    Chief Executive Officer
  • Lindy Durrant
    Chief Scientific Officer, Executive Director
  • Richard Goodfellow
    Executive Director
  • Sally Adams
    Development Director, Director
  • Robert Miller
    Medical Director
  • Gillies O'Bryan-Tear
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.